risperidone has been researched along with Affective Disorders in 31 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (RLAI), adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of mania and/or depression." | 9.15 | Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. ( Adler, CM; Alphs, L; Haskins, JT; Macfadden, W; Turkoz, I; Turner, N, 2011) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 9.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders." | 9.12 | Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. ( Bossie, CA; Dunbar, F; Pandina, GJ; Youssef, E; Zhu, Y, 2007) |
| "In this study we directly compared the efficacy and tolerability of the atypical antipsychotics quetiapine and risperidone in elderly patients with dementia and symptoms of disturbed perception, thought content, mood or behaviour (behavioural and psychological symptoms of dementia-BPSD)." | 9.12 | Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. ( Haushofer, M; Pfolz, H; Rainer, M; Struhal, C; Wick, W, 2007) |
| "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia." | 9.08 | A syndrome of increased affect in response to risperidone among patients with schizophrenia. ( Ashleigh, EA; Larsen, PD, 1998) |
| "The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia." | 8.80 | Effects of risperidone on affective symptoms in patients with schizophrenia. ( De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B, 2000) |
| " We assessed the differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone by using patients treated with haloperidol and fluphenazine as control subjects in whom we would not expect to see an increased risk." | 7.72 | Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. ( Fuller, MA; Grogg, AL; Secic, M; Shermock, KM, 2003) |
| "Risperidone doses were low (0." | 6.69 | Risperidone for young children with mood disorders and aggressive behavior. ( Schreier, HA, 1998) |
| "This pilot study randomly assigned patients with schizophrenia (N=40) to either aripiprazole or risperidone." | 5.15 | An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. ( Aleman, A; Bous, J; Hollander, K; Knegtering, H; Liemburg, E, 2011) |
| "The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (RLAI), adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of mania and/or depression." | 5.15 | Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. ( Adler, CM; Alphs, L; Haskins, JT; Macfadden, W; Turkoz, I; Turner, N, 2011) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 5.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders." | 5.12 | Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. ( Bossie, CA; Dunbar, F; Pandina, GJ; Youssef, E; Zhu, Y, 2007) |
| "In this study we directly compared the efficacy and tolerability of the atypical antipsychotics quetiapine and risperidone in elderly patients with dementia and symptoms of disturbed perception, thought content, mood or behaviour (behavioural and psychological symptoms of dementia-BPSD)." | 5.12 | Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. ( Haushofer, M; Pfolz, H; Rainer, M; Struhal, C; Wick, W, 2007) |
| "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia." | 5.08 | A syndrome of increased affect in response to risperidone among patients with schizophrenia. ( Ashleigh, EA; Larsen, PD, 1998) |
| "The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia." | 4.80 | Effects of risperidone on affective symptoms in patients with schizophrenia. ( De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B, 2000) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| " We assessed the differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone by using patients treated with haloperidol and fluphenazine as control subjects in whom we would not expect to see an increased risk." | 3.72 | Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. ( Fuller, MA; Grogg, AL; Secic, M; Shermock, KM, 2003) |
| "Risperidone was titrated from 0." | 2.76 | An open-label trial of risperidone in children and adolescents with severe mood dysregulation. ( Coelho, R; Krieger, FV; Pheula, GF; Rohde, LA; Tramontina, S; Zeni, CP; Zeni, T, 2011) |
| "Risperidone doses were low (0." | 2.69 | Risperidone for young children with mood disorders and aggressive behavior. ( Schreier, HA, 1998) |
| "Despite the fact that psychiatric illness in the pre-adult era is not rare, few controlled clinical trials have examined the short-term safety and efficacy of these agents in youths with psychosis." | 2.39 | Antipsychotic medications in children and adolescents. ( Findling, RL; Grcevich, SJ; Lopez, I; Schulz, SC, 1996) |
| " Analysis of the ways in which the test results were reportedly utilized revealed that they generally played a supporting role with regard to dosing decisions, rather than being the main influence on clinician behaviour." | 1.38 | Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice. ( Butler, R; Dunbar, L; Miles, W; Pulford, J; Sheridan, J; Wheeler, A, 2012) |
| "Risperidone is an effective short-term pharmacologic agent for controlling steroid-related psychiatric adverse effects when cessation or dose reduction of steroid therapy is not an option." | 1.36 | Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone. ( Dahl, G; Shaw, RJ; Tzuang, D; Ularntinon, S, 2010) |
| "The odds of newly reported type 2 diabetes in patients who received risperidone were not significantly different from those in untreated patients (12-month odds ratio [OR] = 1." | 1.32 | Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. ( Gianfrancesco, F; Grogg, A; Mahmoud, R; Meletiche, D; Wang, RH, 2003) |
| "To compare the side effect profile of risperidone with that of oral haloperidol in patients with no previous exposure to antipsychotic drugs (APDs)." | 1.30 | Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. ( Mazurek, MF; Rosebush, PI, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 14 (45.16) | 29.6817 |
| 2010's | 9 (29.03) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, A | 1 |
| Sinha, S | 1 |
| Narang, A | 1 |
| Chouhan, DK | 1 |
| Gupta, S | 1 |
| Binici, NC | 1 |
| Güney, SA | 1 |
| Marston, L | 1 |
| Nazareth, I | 1 |
| Petersen, I | 1 |
| Walters, K | 1 |
| Osborn, DP | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Benarous, X | 1 |
| Consoli, A | 1 |
| Guilé, JM | 1 |
| Garny de La Rivière, S | 1 |
| Cohen, D | 1 |
| Olliac, B | 1 |
| Jing, Y | 1 |
| Kim, E | 1 |
| You, M | 1 |
| Pikalov, A | 1 |
| Tran, QV | 1 |
| Dunbar, L | 1 |
| Butler, R | 1 |
| Wheeler, A | 1 |
| Pulford, J | 1 |
| Miles, W | 1 |
| Sheridan, J | 1 |
| Ularntinon, S | 1 |
| Tzuang, D | 1 |
| Dahl, G | 1 |
| Shaw, RJ | 1 |
| Liemburg, E | 1 |
| Aleman, A | 1 |
| Bous, J | 1 |
| Hollander, K | 1 |
| Knegtering, H | 1 |
| Krieger, FV | 1 |
| Pheula, GF | 1 |
| Coelho, R | 1 |
| Zeni, T | 1 |
| Tramontina, S | 1 |
| Zeni, CP | 1 |
| Rohde, LA | 1 |
| Macfadden, W | 1 |
| Adler, CM | 1 |
| Turkoz, I | 1 |
| Haskins, JT | 1 |
| Turner, N | 1 |
| Alphs, L | 1 |
| Gianfrancesco, F | 1 |
| Grogg, A | 1 |
| Mahmoud, R | 1 |
| Wang, RH | 1 |
| Meletiche, D | 1 |
| Bokszanska, A | 1 |
| Martin, G | 1 |
| Vanstraelen, M | 1 |
| Holt, G | 2 |
| Bouras, N | 2 |
| Taylor, D | 1 |
| Fuller, MA | 1 |
| Shermock, KM | 1 |
| Secic, M | 1 |
| Grogg, AL | 1 |
| Eren, I | 1 |
| Ozcankaya, R | 1 |
| Altinyazar, V | 1 |
| Ahn, MS | 1 |
| Sims, KB | 1 |
| Frazier, JA | 1 |
| Lambert, M | 1 |
| Conus, P | 1 |
| Schimmelmann, BG | 1 |
| Eide, P | 1 |
| Ward, J | 1 |
| Yuen, H | 1 |
| Schacht, M | 1 |
| Edwards, J | 1 |
| Naber, D | 1 |
| McGorry, PD | 1 |
| Suh, GH | 1 |
| Greenspan, AJ | 1 |
| Choi, SK | 1 |
| Pandina, GJ | 1 |
| Bossie, CA | 1 |
| Youssef, E | 1 |
| Zhu, Y | 1 |
| Dunbar, F | 1 |
| Rainer, M | 1 |
| Haushofer, M | 1 |
| Pfolz, H | 1 |
| Struhal, C | 1 |
| Wick, W | 1 |
| Urbano, M | 1 |
| Spiegel, D | 1 |
| Rai, A | 1 |
| Findling, RL | 1 |
| Grcevich, SJ | 1 |
| Lopez, I | 1 |
| Schulz, SC | 1 |
| Heimberg, C | 1 |
| Yearian, AS | 1 |
| Ashleigh, EA | 1 |
| Larsen, PD | 1 |
| Schreier, HA | 1 |
| Rosebush, PI | 1 |
| Mazurek, MF | 1 |
| Williams, H | 1 |
| Clarke, R | 1 |
| Martin, J | 1 |
| Peuskens, J | 1 |
| Van Baelen, B | 1 |
| De Smedt, C | 1 |
| Lemmens, P | 1 |
| Buckley, PF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for risperidone and Affective Disorders
| Article | Year |
|---|---|
Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD.
Topics: Adolescent; Antipsychotic Agents; Chronic Disease; Evidence-Based Medicine; Female; Humans; Irritabl | 2017 |
Antipsychotic medications in children and adolescents.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Cl | 1996 |
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Comorb | 1998 |
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Adult; Age Factors; Aged; Algorithms; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clini | 1998 |
Effects of risperidone on affective symptoms in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Halop | 2000 |
Broad therapeutic uses of atypical antipsychotic medications.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Child Development Disorders, P | 2001 |
10 trials available for risperidone and Affective Disorders
| Article | Year |
|---|---|
An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Dose-Response Relat | 2011 |
An open-label trial of risperidone in children and adolescents with severe mood dysregulation.
Topics: Adolescent; Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Female; Follow-Up Studies | 2011 |
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Bipolar D | 2011 |
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Comorbidity; Di | 2003 |
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety Disorders; Cross-Over Studies; Dementia; Doub | 2006 |
Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; Female; Human | 2007 |
Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Dibenzothiazepines; Female; Humans; Male; M | 2007 |
Risperidone-associated burning paraesthesia.
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Mood Disorders; Paresthesia; R | 1996 |
A syndrome of increased affect in response to risperidone among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Disease Susceptibility; Follow-Up Studies; Humans; Male; Middl | 1998 |
Risperidone for young children with mood disorders and aggressive behavior.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; | 1998 |
15 other studies available for risperidone and Affective Disorders
| Article | Year |
|---|---|
Waddling Gait: A complication of valproate therapy and a thought beyond vitamin D deficiency.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Epilepsy, Absence; Fem | 2020 |
Epistaxis as an Unexpected Side Effect of Aripiprazole and Risperidone Treatment in Two Children with Two Different Psychiatric Diagnosis.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2017 |
Prescribing of antipsychotics in UK primary care: a cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Child; Cohort St | 2014 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Cost | 2009 |
Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice.
Topics: Antipsychotic Agents; Attitude of Health Personnel; Biotransformation; Community Mental Health Cente | 2012 |
Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Hormonal; Antipsychotic Agents; Child; Dexa | 2010 |
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Data Collection; Diabetes Mellitus, Type 2; Female; Hu | 2003 |
Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Black People; Diabetes Mellitus; Humans; Male; Mood Disorders | 2003 |
Risperidone-induced rabbit syndrome in mood disorder.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Diagnosis, Differential; Hallucinations; Humans; M | 2004 |
Risperidone-induced psychosis and depression in a child with a mitochondrial disorder.
Topics: Adolescent; Depressive Disorder; Epilepsy, Tonic-Clonic; Female; Humans; Mitochondrial Diseases; Moo | 2005 |
Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Analysis of Variance; Antipsychotic Agents; Benzo | 2005 |
Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Ag | 2007 |
Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Mood Disorders; Prospective Studies; Risperid | 1999 |
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Follow-Up St | 2000 |